Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Journal of the National Cancer Institute

Volumn 104, Issue 2, 2012, Pages 159-162

  Perez, Edith A ^a   Dueck, Amylou C ^b   McCullough, Ann E ^b   Reinholz, Monica M ^c   Tenner, Kathleen S ^c   Davidson, Nancy E ^d   Gralow, Julie ^e   Harris, Lyndsay N ^f   Kutteh, Leila A ^g   Hillman, David W ^c   Jenkins, Robert B ^c   Chen, Beiyun ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f YALE UNIVERSITY   (United States)

^g Oncology Associates of Cedar Rapids   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDICAL ONCOLOGY; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84862908745     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr490     Document Type: Article

References (23)

1. Genentech Inc. Herceptin® (trastuzumab) US prescribing information [online]. http://www. gene.com/gene/products/information/pdf/herceptin- prscribing.pdf. Accessed July 16, 2009.
2. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126(7):803-808.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-792. (Pubitemid 32222155)
4. Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J Natl Cancer Inst. 2011;103(2):87-89.
5. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77(2):148-154. (Pubitemid 34118890)
6. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006; 24(19):3032-3038. (Pubitemid 46638937)
7. HercepTest™ [package insert]. Glostrup, Denmark: Dako Corporation; 1998.
8. Pathway® [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.
9. HER2 FISH pharmDx™ [package insert]. Carpinteria, CA: Dako.
10. PathVysion® [package insert]. Abbott Park, IL: Abbott Laboratories.
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-820. (Pubitemid 43290919)
12. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94(11):855-857. (Pubitemid 34705058)
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16): 1659-1672. (Pubitemid 41464705)
14. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(11): 852-854. (Pubitemid 34705057)
15. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. (Pubitemid 41464706)
16. Slamon D, Eiermann W, Robert N, Pienkowski T, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
17. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145. (Pubitemid 350003059)
18. NCCTG N9831 Clinical Trial Registration. National Institutes of Health Clinical Trials Website. http://clinicaltrials.gov/ct2/show/NCT00005970?term= N9831&rank=2. Accessed April 18, 2011.
19. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(32):3366-3373.
20. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer [published online ahead of print October 31, 2011]. J Clin Oncol. doi:10.1200/JCO.2011.36.7045.
21. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. 2003;42(4): 337-347. (Pubitemid 36459811)
22. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557-572.
23. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.